珍宝岛子公司获盐酸莫西沙星片药品注册证书

Core Viewpoint - The company, Zhenbao Island (603567), has received approval from the National Medical Products Administration for its subsidiary Harbin Zhenbao Pharmaceutical Co., Ltd. to market Moxifloxacin Hydrochloride Tablets, indicating a significant advancement in its pharmaceutical offerings [1]. Group 1: Product Approval - The approved drug, Moxifloxacin Hydrochloride Tablets, is indicated for the treatment of various infections, including acute bacterial sinusitis, acute exacerbations of chronic bronchitis, community-acquired pneumonia, and several types of skin and intra-abdominal infections [1]. - The approval highlights the company's commitment to expanding its product portfolio in the pharmaceutical sector, particularly in addressing serious bacterial infections [1].